Genetic Variance and Hypertension Therapy

An NPPA genotype was associated with differences in treatment response and outcome in patients treated with diuretics versus other drug classes.

Genetic variation may hold a key to differing responses to, and outcomes associated with, pharmacologic interventions. One genetic candidate for such disparity in hypertension therapy is the NPPA gene, which encodes the precursor of atrial natriuretic polypeptide. In a post hoc analysis of data from the ALLHAT study, investigators assessed whether the NPPA G664A or the NPPA T2238C polymorphism was associated with different hypertension-treatment outcomes. Genotyping was performed in 38,462 ALLHAT participants who were randomized to receive chlorthalidone (a diuretic), amlodipine (a calcium-channel blocker), lisinopril (an ACE inhibitor), or doxazosin (an alpha-adrenergic blocker).

The NPPA G664A variant was not associated with any difference…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Genetic Variance and Hypertension Therapy

Topics

Reviewing Author